CA3073648A1 - Treatment of abnormal bone conditions in acid sphingomyelinase deficiency patients - Google Patents

Treatment of abnormal bone conditions in acid sphingomyelinase deficiency patients Download PDF

Info

Publication number
CA3073648A1
CA3073648A1 CA3073648A CA3073648A CA3073648A1 CA 3073648 A1 CA3073648 A1 CA 3073648A1 CA 3073648 A CA3073648 A CA 3073648A CA 3073648 A CA3073648 A CA 3073648A CA 3073648 A1 CA3073648 A1 CA 3073648A1
Authority
CA
Canada
Prior art keywords
patient
doses
bone
acid sphingomyelinase
asmd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3073648A
Other languages
English (en)
French (fr)
Inventor
Ana Cristina SCHEIDT-PUGA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Publication of CA3073648A1 publication Critical patent/CA3073648A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
CA3073648A 2017-08-24 2018-08-22 Treatment of abnormal bone conditions in acid sphingomyelinase deficiency patients Pending CA3073648A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762549732P 2017-08-24 2017-08-24
US62/549,732 2017-08-24
EP17306720 2017-12-07
EP17306720.8 2017-12-07
PCT/IB2018/056346 WO2019038685A2 (en) 2017-08-24 2018-08-22 TREATMENT OF ABNORMAL BONE CONDITIONS IN PATIENTS WITH ACIDIC SPHINGOMYELASE DISEASE

Publications (1)

Publication Number Publication Date
CA3073648A1 true CA3073648A1 (en) 2019-02-28

Family

ID=63556374

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3073648A Pending CA3073648A1 (en) 2017-08-24 2018-08-22 Treatment of abnormal bone conditions in acid sphingomyelinase deficiency patients

Country Status (16)

Country Link
US (2) US11898175B2 (https=)
EP (1) EP3672622B1 (https=)
JP (3) JP7216075B2 (https=)
KR (2) KR20250025051A (https=)
CN (2) CN111344003B (https=)
AU (2) AU2018319565B2 (https=)
BR (1) BR112020003541A2 (https=)
CA (1) CA3073648A1 (https=)
CO (1) CO2020001801A2 (https=)
ES (1) ES2970423T3 (https=)
IL (1) IL272757B2 (https=)
MX (2) MX2020002106A (https=)
PL (1) PL3672622T3 (https=)
SG (1) SG11202001544VA (https=)
TW (1) TWI791040B (https=)
WO (1) WO2019038685A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3998078T1 (sl) * 2009-08-28 2026-02-27 Genzyme Corporation Encimsko nadomestno zdravljenje z naraščajočim odmerkom za zdravljenje pomanjkanja kisle sfingomielinaze
KR20250025051A (ko) * 2017-08-24 2025-02-20 사노피 산성 스핑고미엘린분해효소 결핍증 환자에서의 비정상적 골병태의 치료
PY1939780A (es) * 2018-05-25 2019-12-04 Genzyme Corp Composiciones farmacéuticas para el tratamiento de la deficiencia de esfingomielinasa ácida
EP3976218B1 (en) * 2019-05-31 2025-02-19 Genzyme Corporation Two-dimensional lc-ms/ms systems
CN112773779B (zh) * 2021-02-04 2022-08-16 上海交通大学医学院附属新华医院 氨溴索、千金藤和汉防已在治疗酸性鞘磷脂酶缺乏症中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773278A (en) 1991-05-03 1998-06-30 Mount Sinai Medical Center Acid sphingomyelinase gene
CN1302897A (zh) 1999-10-28 2001-07-11 上海博容基因开发有限公司 一种新的多肽——人酸性鞘磷酯酶相似的磷酸二酯酶21和编码这种多肽的多核苷酸
JP2008545752A (ja) * 2005-06-02 2008-12-18 テルシカ インコーポレーティッド 成長障害を処置するための方法
SI3998078T1 (sl) * 2009-08-28 2026-02-27 Genzyme Corporation Encimsko nadomestno zdravljenje z naraščajočim odmerkom za zdravljenje pomanjkanja kisle sfingomielinaze
WO2013130963A1 (en) 2012-03-02 2013-09-06 Shire Human Genetic Therapies, Inc. Compositions and methods for treating type iii gaucher disease
AR093908A1 (es) 2012-12-12 2015-06-24 Teva Pharma Fusion de la hormona de crecimiento humana y albumina, formulacion y usos de la misma
LT3004896T (lt) * 2013-06-07 2020-01-10 Genzyme Corporation Rūgštinės sfingomielinazės sutrikimų žymuo ir jo panaudojimas
KR20250025051A (ko) * 2017-08-24 2025-02-20 사노피 산성 스핑고미엘린분해효소 결핍증 환자에서의 비정상적 골병태의 치료

Also Published As

Publication number Publication date
AU2018319565A1 (en) 2020-04-09
JP7216075B2 (ja) 2023-01-31
EP3672622B1 (en) 2023-11-08
JP2024050732A (ja) 2024-04-10
CN118453843A (zh) 2024-08-09
MX2023010908A (es) 2023-09-27
US11898175B2 (en) 2024-02-13
KR102769578B1 (ko) 2025-02-20
EP3672622A2 (en) 2020-07-01
BR112020003541A2 (pt) 2020-09-01
IL272757A (en) 2020-04-30
NZ762860A (en) 2025-09-26
ES2970423T3 (es) 2024-05-28
IL272757B1 (en) 2024-03-01
JP7431356B2 (ja) 2024-02-14
CN111344003A (zh) 2020-06-26
IL272757B2 (en) 2024-07-01
AU2018319565B2 (en) 2025-02-20
SG11202001544VA (en) 2020-03-30
TWI791040B (zh) 2023-02-01
US20210139868A1 (en) 2021-05-13
MX2020002106A (es) 2020-07-14
CN111344003B (zh) 2024-05-07
KR20200044064A (ko) 2020-04-28
TW201919689A (zh) 2019-06-01
PL3672622T3 (pl) 2024-04-02
WO2019038685A2 (en) 2019-02-28
RU2020111649A (ru) 2021-09-24
JP2023052459A (ja) 2023-04-11
AU2025203384A1 (en) 2025-05-29
JP2020531527A (ja) 2020-11-05
KR20250025051A (ko) 2025-02-20
WO2019038685A3 (en) 2019-05-02
US20240218338A1 (en) 2024-07-04
CO2020001801A2 (es) 2020-04-01

Similar Documents

Publication Publication Date Title
US20240218338A1 (en) Treatment of abnormal bone conditions in acid sphingomyelinase deficiency patients
Schuchman et al. Types A and B niemann-pick disease
Tomatsu et al. Impact of enzyme replacement therapy and hematopoietic stem cell transplantation in patients with Morquio A syndrome
Marcucci et al. Gaucher disease and bone manifestations
US8709408B2 (en) Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency
Langeveld et al. Bone health in patients with inborn errors of metabolism
Campistol et al. Glutaric aciduria type I: unusual biochemical presentation
RU2795570C2 (ru) Лечение патологических состояний кости у пациентов с дефицитом кислой сфингомиелиназы
BR122025022093A2 (pt) Uso de uma esfingomielinase ácida humana recombinante (rhasm) no tratamento de condições ósseas anormais em pacientes com deficiência de esfingomielinase ácida
Broomfield et al. Pulmonary manifestations of endocrine and metabolic diseases in children
Van Baelen et al. Unexplained splenomegaly as a diagnostic marker for a rare but severe disease with an innovative and highly effective new treatment option: A case report
EP4291224A1 (en) Alkaline phosphatase polypeptides and methods of use thereof
Kasapkara et al. The evaluation of skeletal manifestations in patients with Gaucher disease
Lang et al. Metabolic masqueraders of paediatric and adult rheumatic diseases
ALAGIA et al. ACID SPHINGOMYELINASE DEFICIENCY: A COMPLEX AND RARE DISORDER THAT NEEDS CLINICIANS'AWARENESS
Doulgeraki et al. Co-occurrence of two rare diseases: a child with phenylketonuria and WNT1 osteoporosis
Laron et al. Recommended by ISPED and SIMA
Kubaski Diagnosis and therapies for mucopolysaccharidoses
Van Coster et al. P301 Mitochondrial abnormalities in a newborn with lactic acidosis and adrenal calcifications

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220825

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240822

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241101

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241101

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20241119

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250319

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250411

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250717

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250717

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250821

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250821

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260217